title: Raves and risks for erythropoietin.
abstract: Global use of erythropoietin (EPO) continues to increase as a proven agent for the treatment of anemia. Yet, EPO is no longer believed to have exclusive biological activity in the hematopoietic system and is now considered applicable for a variety of disorders such as diabetes, Alzheimer's disease, and cardiovascular disease. Treatment with EPO is considered to be robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. On the converse side, observations that EPO administration is not without risk have fueled controversy. Here we present recent advances that have elucidated a number of novel cellular pathways governed by EPO to open new therapeutic avenues for this agent and avert its potential deleterious effects.
authors.affiliation: Division of Cellular and Molecular Cerebral Ischemia, Department of Neurology, Center for Molecular Medicine and Genetics, Institute of Environmental Health Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA. aa2088@wayne.edu
authors.forename: Kenneth
authors.initials: K
authors.lastname: Maiese
authors.forename: Zhao Zhong
authors.initials: ZZ
authors.lastname: Chong
authors.forename: Yan Chen
authors.initials: YC
authors.lastname: Shang
mesh_terms: D000818:Animals; D017209:Apoptosis; D003920:Diabetes Mellitus / Q000628:therapy; D004921:Erythropoietin / Q000502:physiology* / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D006410:Hematopoiesis; D006801:Humans; D007249:Inflammation; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D019636:Neurodegenerative Diseases / Q000378:metabolism; D018384:Oxidative Stress; D015398:Signal Transduction
chemical_list: D004921:Erythropoietin